Dental Care Clinics in Gallipolis Ferry, WV Accepting Medicare
2 Dental Care Clinics found. Showing 1 - 2
 Valley Health Gallipolis Ferry Dentist Medicare: Not Enrolled in Medicare Practice Location: 15167 Huntington Road, Gallipolis Ferry, WV 25515 Phone: 304-675-5725 Fax: 304-697-2086 |
Valley Health Gallipolis Ferry Dentist Medicare: Not Enrolled in Medicare Practice Location: 15167 Huntington Road, Gallipolis Ferry, WV 25515 Phone: 304-675-5725 Fax: 304-697-2086 |
News Archive
First Edition: March 11, 2013
Kaiser Health News consumer columnist Michelle Andrews answers a reader question about insurance options for people with pre-existing conditions.
Beta-blockers reduce mortality in patients with heart failure and moderate kidney dysfunction
Beta-blockers remain effective for preventing death in heart failure with reduced ejection fraction (HFrEF) and sinus rhythm, even in patients with moderate or moderately-severe kidney dysfunction, according to late breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology.
County-level sociodemographic risk factors associated with COVID-19 incidence and mortality
In just one year, COVID-19 has killed more than 400,000 Americans, and infected more than 24 million others. But a new study shows just how unevenly those deaths and cases have played out across the country.
Saskatchewan government makes insulin detemir more accessible to residents
The Canadian Diabetes Association applauds the Government of Saskatchewan for increasing access to insulin detemir for residents of Saskatchewan living with diabetes. Insulin detemir, also known as Levemir, has been added to the Saskatchewan Drug Formulary, under Exception Drug Status (EDS) effective July 1, 2009. As well, the updated formulary now includes NovoRapid-NOO, Apidra-AVT and Humalog-LIL within its Revised Exception Drug Status Criteria.
Trovagene develops first molecular diagnostic test to detect KRAS mutations from urine samples
Trovagene, Inc. today announced successful development of its first molecular diagnostic test capable of detecting KRAS mutations from a urine specimen. Transfer of the transrenal KRAS test to the company's CLIA lab is expected to be completed in December 2012 with commercial availability expected in January 2013.
› Verified 8 days ago